Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

To provide open-label re-treatment with PROCHYMAL to subjects enrolled in companion Protocol 603 to evaluate the safety in subjects with active Crohn's disease who are resistant to standard Crohn's disease therapies.

Condition or disease	Intervention/treatment	Phase
Crohn's Disease	Drug: adult human mesenchymal stem cells	Phase 3

Detailed Description:

Subjects will receive infusions of PROCHYMAL on Day 42, Day 84, and Day 126 after initial infusion of PROCHYMAL in Protocol 603. Each infusion will contain 200 million cells. As subjects will be required to be in Protocol 603 during the entire duration of their participation in Protocol 611, all concomitant medication and safety information will be monitored by Protocol 603 and the combination of data from the two protocols

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	120 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Study Start Date :	September 2010
Estimated Primary Completion Date :	February 2019
Estimated Study Completion Date :	February 2019

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Prochymal; Infusions of Prochyaml on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.	Drug: adult human mesenchymal stem cells; PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.; Other Names: Prochymal; remestemcel-L

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Disease remission [ Time Frame: 180 Days after first infusion in Protocol 603 ]
   CDAI at or below 150 and increase in IBDQ

Secondary Outcome Measures :

1. Disease Improvement [ Time Frame: 180 Days after first infusion in Protocol 603 ]
   CDAI response to treatments is defined as a CDAI of 150 or below, or a reduction in CDAI of at least 100 points.
2. Improvement in Quality of Life (IBDQ) [ Time Frame: 180 Days after first infusion in Protocol 603 ]
   IBDQ response to treatment is defined as IBDQ of 170 or above, or an increase in IBDQ of at least 16 points.
3. Number of Adverse events as a measure of safety [ Time Frame: 180 Days after first infusion in Protocol 603 ]
4. Infusional toxicity as a measure of safety and tolerability [ Time Frame: 180 Days after first infusion in Protocol 603 ]
   Infusional toxicity will be evaluated by continuously monitoring the subject's vital signs and O2 saturation by pulse oximetry from the time of PROCHYMAL administration until two hours after infusion is complete.

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Subject must have qualified for, enrolled in, and provided written ICF and authorization for use and disclosure of PHI for Protocol 603 after the August 3, 2010.
• Subject successfully completed all screening assessments in Protocol 603 as required by Protocol 603.
• Subject successfully completed the full course of each of the four infusions of investigational agent on Days 0, 3, 7, and 14 of Protocol 603 after August 3, 2010.
• Subject must enroll in Protocol 611 on or before the 45th day after first infusion in Protocol 603.
• Subject must provide written ICF and authorization for use and disclosure of PHI for Protocol 611.

Exclusion Criteria:

• Subject is unwilling or unable to adhere to requirements of Protocol 611.
• Subject had confirmed respiratory distress during a PROCHYMAL infusion in any prior PROCHYMAL study.
• Subject had a serious adverse event in any previous PROCHYMAL study that was deemed by the principal investigator of that study to be possibly or probably related to PROCHYMAL and also that was within 48 h after a PROCHYMAL infusion.

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, California
University of California, San Francisco
San Francisco, California, United States, 94115
United States, Florida
Clinical Research of West Florida
Clearwater, Florida, United States, 33765
Shafran Gastroenterology Center
Winter Park, Florida, United States, 32789
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60611
United States, Kansas
Cotton-O'Neil Clinical Research Center
Topeka, Kansas, United States, 66606
United States, Maryland
University of Maryland, Baltimore
Baltimore, Maryland, United States, 21201
Chevy Chase Clinical Research
Chevy Chase, Maryland, United States, 20815
United States, Missouri
Saint Louis Center for Clinical Research
Saint Louis, Missouri, United States, 63128
St. Louis Center for Clinical Studies
Saint Louis, Missouri, United States, 63128
United States, New Hampshire
Dartmouth HItchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New York
Weill Cornell Medical College
New York, New York, United States, 10028
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, Tennessee
Gastroenterology Center of the Midsouth, PC
Germantown, Tennessee, United States, 38138
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
United States, Virginia
McGuire Research Institute
Richmond, Virginia, United States, 23249
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Australia, Victoria
Royal Melbourne Hospital
Melbourne, Victoria, Australia
New Zealand
University of Otago
Christchurch, New Zealand
Waikato Hospital
Hamilton, New Zealand

Sponsors and Collaborators

Mesoblast International Sàrl

Investigators

Study Director:	Pushpam Bharathi	Mesoblast International Sarl

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Mesoblast International Sàrl
ClinicalTrials.gov Identifier:	NCT01233960 History of Changes
Other Study ID Numbers:	CRD 611
First Posted:	November 3, 2010
Last Update Posted:	December 11, 2017
Last Verified:	December 2017

Keywords provided by Mesoblast, Ltd. ( Mesoblast International Sàrl ):

Crohn's Disease; Adult Stem Cell Therapy; inflammation of the gastrointestinal tract

Additional relevant MeSH terms:

Crohn Disease; Inflammatory Bowel Diseases; Gastroenteritis	Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases